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Introduction: Tick-borne pathogens cause a spectrum of disease manifestations in both dogs and humans.
Recognizing regional and temporal shifts in exposure are important as tick distributions change. To better
delineate regional exposure to canine tick-borne pathogens, an expanded set of species-specific peptides were
used to detect Anaplasma phagocytophilum (Aph), Anaplasma platys (Apl), Ehrlichia canis (Ec), Ehrlichia
chaffeensis (Ech), Ehrlichia ewingii (Eew), and Borrelia burgdorferi (Bb) antibodies in canine serum.
Methods: Archived canine serum samples (n6,582) collected during 20082010 and in 2012 from the US,
Canada, and the Caribbean were retrospectively screened for antibodies against Ehrlichia and Anaplasma
species-specific peptides. Overall, regional and temporal seroprevalence rates were determined.
Results: Overall Bb and Eew were the most seroprevalent pathogens. During 20082010, seroprevalence rates
increased overall for Aph and Ech, and regionally, Bb and Aph seroprevalence rates increased in the South.
Canada had unexpectedly high seroprevalence rates for Ec and Apl. The most common co-exposures were
EewEch, followed by AphBb and EewBb.
Conclusions: This study demonstrated significant shifts in canine vector-borne disease seroprevalence rates.
The use of specific peptides facilitated improved geographic delineation of tick-borne pathogen distributions
among dogs, which may enhance epidemiological surveillance of vector-borne pathogens shared by dogs and
humans.
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C
anine vector-borne diseases (CVBDs) are prevalent
in the US, Canada, and the Caribbean. Tick-borne
pathogens, including Anaplasma phagocytophilum
(Aph), Anaplasma platys (Apl), Ehrlichia canis (Ec), Ehr-
lichia chaffeensis (Ech), Ehrlichia ewingii (Eew), and
Borrelia burgdorferi (Bb), infect dogs and humans, result-
ing in clinical or subclinical infections (17). As tick
distributionschangethroughecosystemfluctuations,wild-
life migration, and increased international transport of
companion animals, diagnosing and managing dog and
human tick-borne diseases has become medically complex
and more challenging. Previous studies indicate that Bb
seroreactive dogs are effective sentinels for human Lyme
disease risk (7, 8). Recognizing risk factors and the
prevalence of single and co-exposures within a particular
regionisepidemiologicallyimportantforpublichealthand
diagnostically important for clinicians. Spatio-temporal
tick-borne pathogen surveillance should identify high-risk
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diagnosis of regionally neglected pathogens, and better
elucidate co-infection risks.
In 2001, IDEXX Laboratories, Inc., developed rapid,
in-houseELISAplatforms(SNAP†3Dx†,SNAP †4Dx†,
and SNAP† 4Dx† Plus), allowing veterinarians to
screen for CVBDs (heartworm disease, Lyme disease,
ehrlichiosis, and anaplasmosis). Species-specific pep-
tides developed to detect canine antibodies to Ec, Ech,
Eew, Aph,a n dApl were used to manufacture a pro-
prietary,researchprototypeELISASNAPassay(SNAP
M-A), showing seroreactivity to individual Anaplasma
spp. and Ehrlichia spp. (912). Archived canine serum
samples submitted between 2008 and 2010 and in 2012
by veterinarians from dogs with suspected tick-borne
disease tothe Vector-Borne Disease Diagnostic Labora-
tory at North Carolina State University (VBDDL
NCSU) were tested using the SNAP M-A. Regional
and temporal seroprevalences within the US, Canada,
and the Caribbean and common co-exposures between
these pathogens are reported.
Methods
Canine serum samples
Archived canine serum samples (n6,582) submitted to
the VBDDLNCSU for serological testing against tick-
borne pathogens between January 2008December 2010
(n6,270; 95.3%) and JanuaryMarch 2012 (n312;
4.7%) were available for SNAP M-A testing and analysis.
Samples submitted from the same dog within 5 weeks
of the initial submission were excluded. Available infor-
mation included signalment (age, breed, and sex), date of
sample collection, and owner or veterinary practice address.
Regions, states, and provinces are defined in Table 1.
Serology
All canine sera were retrospectively tested by SNAP M-A
for the simultaneous and individual detection of specific
Ec, Ech, Eew, Aph, Apl, and Bb antibodies. Included on
SNAP M-A are two additional spots containing a com-
bination of Anaplasma spp. synthetic peptides, labeled A-
genus, and Ehrlichia spp. (Ec and Ech only) synthetic
peptides, labeled E-genus. SNAP M-A uses a reversible
chromatographic flow of sample and automatic, sequen-
tial flow of wash solution and enzyme substrate. Archived
canine serum stored at 808C was thawed to room tem-
perature prior to mixing four drops of serum with 45
drops of SNAP M-A conjugate. The mixture was allowed
to move across a flow matrix where peptide-specific
antibody could bind to peptide-HRP conjugate before
color reactant release. Color development indicating a
positive reaction was read after 15 min.
Statistical analysis
Seroprevalence, defined as the number of seropositive
samples divided by the number of samples tested, was
calculated by region, month, and year. The Chi-squared
test or Fisher exact test was used to determine significant
differences in the proportions of seroreactivity by region,
month, and year. Multiple comparisons were performed
using the Multtest procedure in SAS/STAT v.9.3 (SAS
Institute, Cary, NC). Regions were assigned into the fol-
lowing categories based on owner or veterinary hospital
address: Northeast, Mid-Atlantic, South, Midwest, West,
Canada, and the Caribbean region, which includes all
countries and territories in and around the Caribbean
Sea. State-wide seroprevalence was calculated for states
with at least 30 sample submissions and depicted in heat
maps (openheatmap.com). The proportion of co-exposures,
defined as the number of dogs with two or more sero-
positive results divided by the total number of dogs,
was calculated. The following positive species-specific
peptide combinations were not considered co-exposures:
E-genusEch,E - g e n u s Ec,A - g e n u s Apl,o rA - g e n u s 
Aph. Odds ratios (ORs) and 95% confidence intervals
(95% CI) were used as measures of association between
exposure to one pathogen and exposure to a second patho-
gen (representing concurrent or sequential co-exposures).
Level of significance was established at pB0.05. Statis-
tical analyses were performed using SAS/STAT 9.3 (SAS
Institute Inc., Cary, NC).
Results
A total of 6,582 dog serum samples were tested, includ-
ing 6,268 (95.2%) from the US, representing 43 states;
285 (4.3%) from Canada, representing seven provinces;
and 29 (0.44%) from the Caribbean region (Table 1).
Exposure to at least one tick-borne pathogen was docu-
mented in 1,198 (18.2%) dogs. Of the 6,582 sera tested,
exposures included Bb (n545, 8.3%), Eew (n251, 3.8%),
Aph (n227, 3.4%), Ech (n202, 3.1%), Ec (n117,
1.8%), and Apl (n99, 1.5%) (Table 1). E-genus and
A-genus antibodies were detected in 327 (5.0%) and 238
(3.6%) dogs, respectively. Of the E-genus and A-genus
antibody positives, 50 (15.3%) and 32 (13.4%) dogs, re-
spectively, did not have species-specific antibodies, which
could represent dogs with low Ehrlichia and Anaplasma
species-specific antibody titers or potentially, seroreactivity
to a species, such as Ehrlichia muris or the Panola mountain
Ehrlichia not specifically tested for in this study.
Seroprevalences by region are reported in Table 1. The
greatest proportion of samples were submitted from
the South (n3,011, 45.7%), followed by the Midwest
(n1,162, 17.7%), the Mid-Atlantic (n1,065, 16.2%),
the Northeast (n532, 8.1%), the West (n498, 7.6%),
Canada (n285, 4.3%), and the Caribbean (n29, 0.44%).
Regional comparisons documented significantly higher
Bb exposure frequencies in the Northeast (n122, 22.9%)
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seroreactivity to Ehrlichia canis (Ec), E. ewingii (Eew), E. chaffeensis (Ech), Anaplasma platys (Apl), A. phagocytophilum (Aph),
Borrelia burgdgorferi (Bb), Anaplasma spp. (A-genus), and Ehrlichia spp. (E-genus)
Sample origin Sample # Eew (%) Ech (%) Ec (%) Apl (%) Aph (%) Bb (%) A-genus (%) E-genus (%)
Overall 6,582 251 (3.8) 202 (3.1) 117 (1.8) 99 (1.5) 227 (3.5) 545 (8.3) 238 (3.6) 327 (5)
South 3,011 156 (5.2) 129 (4.3) 70 (2.3) 59 (2) 64 (2.1) 100 (3.3) 80 (2.7) 209 (6.9)
FL 501 15 (3) 11 (2.2) 13 (2.6) 12 (2.4) 10 (2) 8 (1.6) 19 (3.8) 21 (4.2)
GA 162 12 (7.4) 6 (3.7) 2 (1.2) 1 (0.6) 3 (1.9) 6 (3.7) 3 (1.9) 6 (3.7)
NC 1,014 104 (10.3) 96 (9.5) 19 (1.9) 22 (2.2) 25 (2.5) 55 (5.4) 26 (2.6) 120 (11.8)
SC 93 8 (8.6) 7 (7.5) 0 1 (1.1) 1 (1.1) 5 (5.4) 2 (2.2) 7 (7.5)
AL 40 1 (2.5) 0 3 (7.5) 1 (2.5) 0 0 0 2 (5)
AR 36 2 (5.6) 1 (2.8) 0 0 0 0 0 2 (6)
KY 69 3 (4.3) 2 (2.9) 0 1 (1.4) 0 4 (5.8) 1 (1.4) 5 (7.2)
LA 27 1 (3.7) 1 (3.7) 1 (3.7) 0 0 0 1 (3.7) 1 (3.7)
MS 16 0 0 0 1 (6.3) 0 0 0 1 (6.3)
OK 42 6 (14.3) 0 1 (2.4) 0 1 (2.4) 0 1 (2.4) 4 (9.5)
TN 45 1 (2.2) 0 1 (2.2) 1 (2.2) 3 (6.7) 2 (4.4) 0 4 (8.9)
TX 966 3 (0.3) 5 (0.5) 30 (3.1) 19 (2) 21 (2.2) 20 (2.1) 27 (2.8) 36 (3.7)
Mid-Atlantic 1,065 61 (5.7) 59 (5.5) 9 (0.8) 12 (1.1) 58 (5.4) 236 (22.2) 55 (5.2) 60 (5.6)
VA 656 45 (6.9) 32 (4.9) 6 (0.9) 7 (1.1) 28 (4.3) 133 (20.3) 30 (4.6) 38 (5.8)
MD 313 12 (3.8) 25 (8) 3 (1) 4 (1.3) 25 (8) 78 (24.9) 21 (6.7) 20 (6.4)
DE 4 0 0 0 0 0 1 (25) 0 0
DC 90 4 (4.4) 2 (2.2) 0 1 (1.1) 5 (5.6) 24 (26.7) 4 (4.4) 2 (2.2)
WV 2 0 0 0 0 0 0 0 0
Northeast 532 18 (3.4) 5 (0.9) 3 (0.6) 8 (1.5) 69 (13) 122 (22.9) 54 (10.2) 10 (1.9)
CT 48 1 (2.1) 2 (4.2) 2 (4.2) 0 12 (25) 16 (33.3) 11 (22.9) 3 (6.3)
MA 35 0 0 0 1 (2.9) 5 (14.3) 14 (40) 4 (11.4) 0
ME 4 0 0 0 1 (25) 0 1 (25) 0 0
NH 19 0 0 0 0 1 (5.3) 5 (26.3) 1 (5.3) 0
VT 6 0 0 0 0 2 (33.3) 2 (33.3) 1 (16.7) 0
NJ 12 0 0 0 0 1 (8.3) 4 (33.3) 1 (8.3) 0
NY 205 10 (4.9) 2 (1) 0 1 (0.5) 33 (16.1) 35 (17.1) 24 (11.7) 4 (2)
PA 203 7 (3.4) 1 (0.5) 1 (0.5) 5 (2.5) 15 (7.4) 45 (22.2) 12 (5.9) 3 (1.5)
Midwest 1,162 14 (1.2) 8 (0.7) 6 (0.5) 7 (0.6) 22 (1.9) 66 (5.7) 31 (2.7) 20 (1.7)
MI 20 0 0 0 0 0 0 0 1 (5)
OH 430 2 (0.5) 1 (0.2) 1 (0.2) 3 (0.7) 3 (0.7) 16 (3.7) 7 (1.6) 5 (1.2)
IN 93 1 (1.1) 1 (1.1) 0 0 2 (2.2) 9 (9.7) 3 (3.2) 2 (2.2)
IL 383 4 (1) 2 (0.5) 1 (0.3) 4 (1) 7 (1.8) 23 (6) 12 (3.1) 5 (1.3)
WI 58 0 0 0 0 6 (10.3) 7 (12.1) 5 (8.6) 0
MN 8 0 0 1 (12.5) 0 2 (25) 2 (25) 1 (12.5) 0
IA 78 3 (3.8) 0 0 0 1 (1.3) 9 (11.5) 2 (2.6) 1 (1.3)
MO 36 2 (5.6) 3 (8.3) 1 (2.8) 0 0 0 0 4 (11.1)
KS 53 2 (3.8) 1 (1.9) 1 (1.9) 0 1 (1.9) 0 0 1 (1.9)
NE 3 0 0 1 (33.3.) 0 0 0 1 (33.3) 1 (33.3)
West 498 2 (0.4) 1 (0.2) 12 (2.4) 5 (1) 10 (2) 15 (3) 6 (1.2) 10 (2.0)
AZ 15 1 (6.7) 0 0 0 0 1 (6.7) 0 0
CA 121 0 0 0 0 4 (3.3) 3 (2.5) 1 (0.8) 0
CO 246 1 (0.4) 0 9 (3.7) 3 (1.2) 5 (2) 10 (4.1) 4 (1.6) 8 (3.3)
NM 61 0 1 (1.6) 1 (1.6) 0 1 (1.6) 1 (1.6) 0 1 (1.6)
NV 5 0 0 0 0 0 0 0 0
OR 35 0 0 0 1 (2.9) 0 0 0 0
UT 2 0 0 1 0 0 0 0 1
WA 12 0 0 0 0 0 0 0 0
WY 1 0 0 1 1 0 0 1 0
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the Midwest (n66, 5.7%; pB0.001 and pB0.001, res-
pectively) and the South (n100, 3.3%; pB0.001 and
pB0.001, respectively). Aph seroprevalence was signifi-
cantly higher in the Northeast (n69, 13%) and the
Mid-Atlantic (n58, 5.5%) when compared with other
regionsintheUS(pB0.01,allcomparisons).EewandEch
exposures were most prevalent in Mid-Atlantic (n61,
5.7%; n59, 5.5%, respectively) and Southern dogs
(n156, 5.2%; n129, 4.3%, respectively) compared
to the Midwest (n14, 1.2%; n8, 0.7%, respectively)
(pB0.001 for all comparison listed) and did not signifi-
cantly differ across the Mid-Atlantic and Southern re-
gions. Ec prevalence was low among all US and Canadian
regions (ranging from 0.5 to 3.2%), with the highest
prevalence in the West (n12; 2.4%) and Canada (n9,
3.2%). The Caribbean had a significantly higher Ec
seroprevalence (n8, 27.6%) than all other regions
(pB0.001, all comparisons). The Apl seroprevalence
ranged from a high of 10.3% (n3) in the Caribbean to
a low of 0.6% (n7) in the Midwest.
Duetothelackofcomplete2012datafortheentireyear,
significant differences in overall and regional seropreva-
lences were evaluated by year and month using only data
from years 2008 (n2,327; 35.4%), 2009 (n2,184;
33.2%), and 2010 (n1,759; 27%) (Table 2). There were
significant differences in the overall Aph, Anaplasma spp.,
and Ech seroprevalences by year (pB0.0001, p0.0024,
and p0.0004, respectively). Overall Ech exposure ap-
pearedtodeclinefrom2008to2009,butincreasedin2010,
while Aph increased. Regionally, significant increases in
seroprevalence were observed in the Mid-Atlantic, includ-
ingAph(p0.0026), andthe South,including Aph andBb
(pB0.0001 and pB0.0001, respectively). The South also
had significant changes in Ech and Eew seroprevalences,
with a decline in Eew and Ech exposure in 2009 followed
by an increase in 2010 (p0.0191 and p0.0001, res-
pectively). No significant changes or trendswere observed
when seroprevalences were compared between months
(data not shown). Seroprevalence was determined for
each state within the US (Table 1). States with no sam-
ple submissions included HI, AK, MT, ID, SD, and
ND. Heat maps of the US were generated when in-state
seroprevalence data were based upon ]30 submissions
(Figs. 13).
Co-exposures, defined as seroreactivity to more than
one Anaplasmaspp.,Ehrlichia spp., or Bb, were detected in
261 dogs (4.0%). Seroreactivity to two pathogens occurred
in207dogs(3.1%);threepathogensin44dogs(0.7%);four
pathogensinsevendogs(0.1%);andfivepathogensinthree
dogs (0.05%). The most common co-exposures included
EewEch (n91, 1.4%); AphBb (n76, 1.2%); and
EewBb (n41, 0.6%), in contrast to EcApl (n18,
0.3%) (Table 3). Notable regional co-exposures included
AphBbin theNortheast(n33;6.2%), EewEch inthe
South(n62;2.1%)andMid-Atlantic (n22;2.1%).The
Mid-Atlantic had the highest co-exposure seroprevalence
rates for several unexpected pathogen combinations in-
cluding EewBb (n19; 1.8%), EchBb (n17; 1.6%),
and EchAph (n12; 1.1%) (Table 3). ORs identified
associations among CVBD co-exposures (Table 3). The
highest ORswere found among pathogens known to share
a common tick vector (EewEch:O R 31.9, 95%
CI23.243.8; EcApl: OR14.3, 95% CI8.3
24.8). The OR for AphBb (OR6.2, 95% CI4.6
8.3) was lower by comparison. The lower ORs were found
among unexpected combinations of pathogens (EcBb:
OR 0.2, 95% CI 0.050.8; AplBb:O R2.2, 95%
CI 1.33.7; and EcEch:O R2, 95% CI 0.94.5)
(Table 3).
Table 1 (Continued)
Sample origin Sample # Eew (%) Ech (%) Ec (%) Apl (%) Aph (%) Bb (%) A-genus (%) E-genus (%)
Canada 285 0 0 9 (3.2) 5 (1.8) 3 (1.1) 6 (2.1) 5 (1.8) 9 (3.2)
BC 53 0 0 1 (1.9) 1 (1.9) 0 1 (1.9) 1 (1.9) 1 (1.9)
AB 48 0 0 0 1 (2.1) 0 1 (2.1) 0 1 (2.1)
MB 4 0 0 0 0 0 0 0 0
ON 166 0 0 6 (3.6) 3 (1.8) 3 (1.8) 4 (2.4) 4 (2.4) 6 (3.6)
PE 1 0 0 0 0 0 0 0 0
QC 6 0 0 1 (16.7) 0 0 0 0 1 (16.7)
SK 7 0 0 1 (14.3) 0 0 0 0 0
Caribbean 29 0 0 8 (27.6) 3 (10.3) 1 (3.4) 0 7 (24.1) 9 (31)
*p B0.0001 B0.0001 B0.0001 0.0249 B0.0001 B0.0001 B0.0001 B0.0001
Bolded row represents all regions combined (overall).
Shaded rows represent individual regions.
*P-value calculated for regional differences without Caribbean values; P-values remained B0.05 when calculated without Canadian or
Caribbean values.
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This study utilized a panel of species-specific, CVBD
peptides to determine regional seroprevalences in dogs
with suspected tick-borne pathogen exposure. Ec, Ech,
Eew, Aph, Apl, and Bb peptides were designed to detect
species-specific antibodies, so as to facilitate identification
ofuniquepatternsofCVBDexposureindogserafromthe
US, Canada, and the Caribbean (912). Significant
regional changes and various co-exposure patterns were
identified overall, regionally and during 20082010; how-
ever, significant patterns were not observed between
months or seasons (data not shown) of the year, likely
because these data do not represent infection onset.
Limitations of this study include the following: Sample
submission was not proportional across regions with a
near majority of specimens submitted from the Southern
Table 2. Seroprevalence per year between 2008 and 2010 in the US, Canada, and Caribbean to Ehrlichia canis (Ec), E. ewingii (Eew), E.
chaffeensis (Ech), Anaplasma platys (Apl), A. phagocytophilum (Aph), Borrelia burgdgorferi (Bb), Anaplasma spp. (A-genus), and
Ehrlichia spp. (E-genus)
Years (20082010) Sample # Eew (%) Ech (%) Ec (%) Apl (%) Aph (%) Bb (%) A-genus (%) E-genus (%)
Overall
2008 2,327 91 (3.9) 77 (3.3) 43 (1.8) 40 (1.7) 52 (2.2) 191 (8.2) 76 (3.3) 107 (4.6)
2009 2,184 67 (3.1) 43 (2.0) 36 (1.6) 27 (1.2) 73 (3.3) 165 (7.6) 67 (3.1) 103 (4.7)
2010 1,759 78 (4.4) 72 (4.1) 35 (2.0) 28 (1.6) 96 (5.5) 170 (9.7) 88 (5.0) 103 (5.9)
p 0.073 0.0004 0.721 0.395 B0.0001 0.055 0.0024 0.14
South
2008 1,030 57 (5.5) 49 (4.8) 29 (2.8) 25 (2.4) 15 (1.5) 24 (2.3) 29 (2.8) 68 (6.6)
2009 1,041 37 (3.6) 23 (2.2) 25 (2.4) 16 (1.5) 14 (1.3) 20 (1.9) 19 (1.8) 62 (6.0)
2010 761 48 (6.3) 47 (6.2) 14 (1.8) 14 (1.8) 32 (4.2) 46 (6.0) 28 (3.7) 68 (8.9)
p 0.0191 0.0001 0.411 0.3309 B0.0001 B0.0001 0.0525 0.0412
Mid-Atlantic
2008 472 26 (5.5) 24 (5.1) 4 (0.8) 5 (1.1) 14 (3.0) 102 (21.6) 21 (4.4) 25 (5.3)
2009 334 17 (5.1) 15 (4.5) 1 (0.3) 4 (1.2) 24 (7.2) 77 (23.1) 18 (5.4) 18 (5.4)
2010 231 17 (7.4) 20 (8.7) 4 (1.7) 3 (1.3) 20 (8.7) 54 (23.4) 16 (6.9) 16 (6.9)
p 0.4935 0.0817 0.1959 0.9583 0.0026 0.829 0.3863 0.6536
Northeast
2008 202 3 (1.5) 1 (0.5) 0 6 (3.0) 17 (8.4) 45 (22.3) 17 (8.4) 1 (0.5)
2009 162 7 (4.3) 2 (1.2) 0 2 (1.2) 24 (14.8) 37 (22.8) 15 (9.3) 5 (3.1)
2010 153 8 (5.2) 2 (1.3) 3 (2.0) 0 25 (16.3) 36 (23.5) 19 (12.4) 4 (2.6)
p 0.1 0.6785 n/a 0.0745 0.0551 0.962 0.43 0.1562
Midwest
2008 409 5 (1.2) 3 (0.73) 3 (0.73) 1 (0.24) 5 (1.2) 16 (3.9) 7 (1.7) 7 (1.7)
2009 382 6 (1.6) 2 (0.52) 0 2 (0.52) 7 (1.8) 26 (6.8) 8 (2.1) 8 (2.1)
2010 322 3 (0.93) 3 (0.93) 2 (0.62) 4 (1.2) 10 (3.1) 23 (7.1) 16 (5.0) 4 (1.2)
p 0.79 0.9 0.28 0.27 0.18 0.11 0.02 0.36
West
2008 88 0 0 3 (3.4) 1 (1.1) 1 (1.1) 1 (1.1) 1 (1.1) 1 (1.1)
2009 168 0 1 (0.6) 6 (3.6) 1 (0.6) 3 (1.8) 3 (1.8) 1 (0.6) 6 (3.6)
2010 209 2 (0.96) 0 3 (1.4) 3 (1.4) 6 (2.9) 10 (4.8) 4 (1.9) 3 (1.4)
p n/a n/a 0.34 0.84 0.59 0.12 0.5242 0.36
Canada
2008 119 0 0 2 (1.7) 2 (1.7) 0 3 (2.5) 0 3 (2.5)
2009 85 0 0 1 (1.2) 1 (1.2) 1 (1.2) 2 (2.4) 1 (1.2) 1 (1.2)
2010 74 0 0 6 (8.1) 2 (2.7) 2 (2.7) 1 (1.4) 4 (5.4) 5 (6.8)
p n/a n/a 0.03 0.73 0.11 0.8532 0.01 0.17
Caribbean
2008 7 0 0 2 (28.6) 0 0 0 1 (14.3) 2 (28.6)
2009 12 0 0 3 (25.0) 1 (8.3) 0 0 5 (41.7) 3 (25)
2010 9 0 0 3 (33.3) 2 (22.2) 1 (11.1) 0 1 (11.1) 3 (33.3)
p n/a n/a 1 0.44 n/a n/a 0.289 1
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(7.6%), Canada (4.3%), and the Caribbean (0.4%). Speci-
mens were regionalized based on local veterinary hospital
orownerzipcodes,andindividualdogtravelhistorieswere
not available. All samples from NCSU-College of Veter-
inary Medicine were regionalized according to owner zip
codes; however, 21% (n1,353) of samples submitted
from other veterinary teaching hospitals may not accu-
rately represent local exposure, since clients may travel
farther distances for specialized services offered at large
teaching hospitals. As this convenience sample was sub-
mitted to the VBDDL from dogs suspected of a CVBD,
seroprevalence rates are most likely higher than in the
general dog population.
Bb (8.3%), the etiologic agent of Lyme disease, was the
most seroprevalent pathogen in this convenience sample
of dogs (n6,582). This finding is consistent with a
recent study involving a large cohort of dogs from the
Fig. 1. Seroprevalence by state of Borrelia burgdorferi (Bb)o rAnaplasma phagocytophilum (Aph) in dogs suspected of canine vector-
borne disease.
Barbara A. Qurollo et al.
6
(page number not for citation purpose)
Citation: Infection Ecology and Epidemiology 2014, 4: 24699 - http://dx.doi.org/10.3402/iee.v4.24699US that reported an overall canine Bb seroprevalence,
defined as seroreactivity to C6 peptide, of 7.2% (509,195/
6,996,197) (13). This is an increase from an earlier, similar
study, which showed an overall canine Bb seroprevalence
of 5.1% (49,817/982,336) (14). Lyme disease is the most
prevalent tick-borne disease in humans in the US and
has historically been confined to Northeast and upper
Midwestern regions of the country (15, 16). Notably, we
documented a statistical increase in Bb seroprevalence
from 2008 to 2010 in the South (pB0.0001) (Table 2), a
region not historically endemic for Bb infection. A study
by Duncan et al. using a convenience sample from sick
dogs submitted for testing to the VBDDL between 2001
and 2003 measured a lower seroprevalence of Bb, defined
as C6 seroreactivity, in individual Southern states, includ-
ing, NC (0.4%), VA (8.7%), and MD (14.4%) than the Bb
seroprevalences reported in this study (NC, 5.4%; VA,
20.3%; MD, 24.9%) (8). Notably, the seroprevalence of
Bb in northern states was more similar between the two
studies (25% vs. 22.2%, respectively, in PA) suggesting the
differences in the South are more likely due to prevalence
changes and less likely testing variations. Our study
Fig. 2. Seroprevalence by state of Ehrlichia canis (Ec)o rAnaplasma platys (Apl) in dogs suspected of canine vector-borne disease.
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Atlantic (n236; 22.2%), a region bordering the South,
to approximate the Bb seroprevalence in the Northeast
(n122; 22.9%) (p0.99). Furthermore, one third
(n1,014; 34%) of the samples from the South in this
study were collected from dogs residing in NC, a state
that borders VA, where according to the CDC, an
increase in Lyme disease incidence had been reported in
recent years (17). Recently, VA established five counties
along the NC border endemic for Lyme disease (18, 19).
The increased Bb seroprevalence observed in dogs from
the Southern US supports a potential trend for Bb
expansion southward, warranting further studies to
monitor Lyme disease in both dogs and humans south
of Mid-Atlantic States. The CDC reports the approx-
imate distribution of I. scapularis extends from Texas
to the Southeast, Mid-Atlantic, Northeast, and upper
Midwestern states, and a recent report has documented
population increases in Canada (20, 21). We found a Bb
seroprevalence of 2.1% (n6) within our Canadian dog
Fig. 3. Seroprevalence by state of Ehrlichia ewingii (Eew)o rE. chaffeensis (Ech) in dogs suspected of canine vector-borne disease.
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odds ratios (OR) with 95% conﬁdence interval (CI) to Ehrlichia canis (Ec), E. ewingii (Eew), E. chaffeensis (Ech), Anaplasma platys
(Apl), A. phagocytophilum (Aph), and Borrelia burgdgorferi (Bb)
Co-exposure
aOverall South Mid-Atlantic Northeast Midwest West Canada Caribbean
n6,582 n3,011 n1,065 n532 n1,162 n498 n285 n29
EwEch 91 (1.4) 62 (2.1) 22 (2.1) 4 (0.8) 3 (0.3) 0 0 0
OR 31.9
95% CI 23.243.8
AphBb 76 (1.2) 17 (0.6) 19 (1.8) 33 (6.2) 5 (0.4) 2 (0.4) 0 0
OR 6.2
95% CI 4.68.3
EwBb 41 (0.6) 19 (0.6) 19 (1.8) 3 (0.6) 0 0 0 0
OR 2.3
95% CI 1.63.2
EchBb 36 (0.5) 17 (0.6) 17 (1.6) 2 (0.4) 0 0 0 0
OR 2.5
95% CI 1.76.3
EchAph 29 (0.4) 14 (0.5) 12 (1.1) 3 (0.6) 0 0 0 0
OR 5.2
95% CI 3.48.0
AphApl 25 (0.4) 11 (0.4) 4 (0.4) 6 (1.1) 1 1 1 1
OR 9.9
95% CI 6.116
EwAph 24 (0.4) 11 (0.4) 6 (0.6) 6 (1.1) 0 1 0 0
OR 3.2
95% CI 2.05.0
EcApl 18 (0.3) 10 (0.3) 1 (0.09) 0 0 3 (0.6) 3 (1.0) 1
OR 14.3
95% CI 8.324.8
AplBb 17 (0.3) 7 (0.2) 4 (0.4) 5 (0.9) 1 0 0 0
OR 2.2
95% CI 1.33.7
AplEw 13 (0.2) 5 (0.2) 4 (0.4) 2 (0.4) 1 1 0 0
OR 4
95% CI 2.27.2
AplEch 13 (0.2) 9 (0.3) 2 (0.2) 1 1 0 0 0
OR 5
95% CI 2.99.2
EcAph 12 (0.2) 5 (0.2) 2 (0.2) 1 1 0 2 (0.7) 1
OR 3.3
95% CI 1.86.1
EcEw 10 (0.2) 9 (0.3) 1 0 0 0 0 0
OR 2.4
95% CI 1.34.7
EcEch 7 (0.1) 6 (0.2) 0 0 0 1 0 0
OR 2
95% CI 0.94.5
EcBb 2 (0.03) 0 1 1 0 0 0 0
OR 0.2
95% CI 0.050.8
aOR and 95% CI calculated for overall co-exposures only.
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seroreactivity to C6 peptide reported lower Bb seropre-
valences in Canada; canine sera collected from southern
Ontario and Quebec between 2000 and 2003 (n108)
reported Bb seroprevalence as 1.85%, while another study
in 2008 that included all provinces found an overall
seroprevalence of 0.72% (n624) (22, 23). The increased
seroprevalence could be related to differences in testing
platforms, health status of the dogs, population number
and distribution differences and possibly a northern
movement of Bb infected ticks. In 2009, Lyme disease
became a nationally reportable disease in Canada, with
reports of increasing incidence in people (24, 25). Inter-
estingly, a study in dogs using SNAP† 3Dx† and 4Dx†
showed the incidence of Lyme in dogs from ON in 2006
(0.36) and 2007 (0.58) is approximate to the incidence
reported in people from ON in 2006 (0.35) and 2007
(0.58) (25, 26). These data further support the use of dogs
as sentinels for Bb exposure in people.
This study documented a significant increase in canine
exposure to Aph in the US from 2008 to 2010 (pB0.0001)
(Table 2), suggesting a progressively increased risk for
human Aph exposure. These data are supported by the
substantial(53%)increaseofreportedhumangranulocytic
anaplasmosis cases described by the CDC from 2009 to
2010 (2729). Furthermore, canine Aph seroprevalences
were high in the Northeast (n69; 13%), Mid-Atlantic
(n58;5.4%)andtheMidwesternstate,WI(n6;10.3%)
emphasizing the potential utility of dog data for esta-
blishing real-time regional human Aph exposure risk.
The South had a higher Aph seroprevalence (2.1%) than
previous reports that documented Anaplasma spp. (n496;
0.5% and n1,631,332; 0.9%) (13, 14); the discrepancy, in
part, could be due to a greater number of sick dogs in this
sample set, while the former studies included a larger
population of healthy dogs. We identified a significant
increase in Aph seroprevalence from 2008 to 2010 in the
Mid-Atlantic (pB0.0001) and the South (pB0.0001),
consistent with Bb seroprevalence trends for the Southern
region. Like Bb, Aph is not endemic in the South. Studies
reporting the molecular presence of Aph in ticks from
the South found Aph DNA in 1.3% of I. scapularis
ticks and 2.7% of A. americanum ticks collected from
rodents in Florida (30); another study found 1.6% Aph
DNA in I. scapularis ticks collected in SC, GA and
FL, with the highest prevalence (20%) identified in
ticks collected along the GA coast, a documented avian
flyway (31).
Despite similar Aph and Bb seroprevalence trends and a
significant AphBb co-exposure pathogen association
(OR6.2; 95% CI4.68.3), overall the Aph (3.5%) and
Bb (8.3%) seroprevalences differed significantly (p50.001).
Correspondingly,theprevalenceofAph DNAinI.scapularis
ticks collected in NJ was much lower than Bb (6.1% (n9)
and 50.3% (n74), respectively) (32). In this study, Bb
seroprevalencewas found to be similar among dogs from the
Mid-Atlantic (22.2%) and the Northeast (22.9%) (p0.99);
however, the Aph seroprevalence differed significantly be-
tween the two regions (Mid-Atlantic; 5.4% (n58) and
Northeast; 13% (n69) (p50.001), potentially reflecting a
lessprevalentAphinfectionofticksintheMid-Atlanticwhen
compared to the Northeast.
We identified Eew (3.8%) as the most common
Ehrlichia exposure in dogs, followed by Ech (3.1%) and
Ec (1.8%), which is consistent with a 2010 study that
found Eew (5.1%) as the most seroprevalent Ehrlichia
spp. pathogen in a large population of dogs from North
America (n8,622), when compared to Ech (2.8%) and
Ec (0.8%) (9). A similar study in dogs from the south
central US (n143) detected much higher Eew (44.8%)
and Ech (17.5%) seroprevalences and a similar Ec (1.4%)
seroprevalence (33). In this study, overall Ech seropre-
valence varied significantly over time with an initial
decrease and then increase in 2010; seroprevalence
rates were determined to be 3.3% (n77) in 2008,
2.0% (n43) in 2009, and 4.1% (n72) in 2010
(p0.0004) (Table 2). This pattern was observed in three
regions, the South, Mid-Atlantic and Midwest, in which
A. americanum ticks are prevalent. Reported Ech human
monocytic ehrlichiosis (HME) cases increased before
a significant drop in 2010 (2729), which did not mirror
our canine Ech seroprevalence. Regionally, however,
the high prevalence of HME cases was largely similar
to dog Ech seroprevalence, with highest exposure risk
in the South and Mid-Atlantic (2729). In the South,
canine Eew seroprevalence also showed statistically sig-
nificant changes over 2008 (n57; 5.5%), 2009 (n37;
3.6%), and 2010 (n48; 6.3%) (p0.02) (Table 2),
which mirrored the trend for human Eew cases (Eew
ehrlichiosis) for 20082010 (2729). The difficulty in
clinically distinguishing between HME and Eew ehrli-
chiosis, along with the low number of human Eew
infection reports could complicate comparisons made
between canine and human Eew exposure (5, 28); never-
theless, reports of high canine Eew seroprevalences
should prompt more consideration for greater Eew ex-
posure risk in humans throughout much of the Central
and Southern US. In 2008, CDC made Eew ehrlichiosis
a reportable disease in humans (29).
Overall, Ec(n117; 1.8%) and Apl (n99; 1.5%) had the
lowest seroprevalences in dogs from the US. Exposure
frequencies were high in the Caribbean (n8; 27.6% and
n3; 10.3%, respectively), as expected, where R. sanguineus,
the known vector for Ec and potential vector for Apl,
is prevalent. A previous study reported high Ec sero-
(43.8%) and PCR (24.7%) prevalences in the Caribbean (4).
R. sanguineus is rarely documented in Canada (34); however,
Canada had unexpectedly high Ec and Apl seroprevalences
(n9; 3.2% and n5; 1.8%, respectively), potentially due to
a reporting bias from low numbers tested in this study or
Barbara A. Qurollo et al.
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Ec and Apl endemic regions. Efforts to relocate homeless
animals, particularly from tropical regions, including the
Caribbean, to the Northeastern US and Canada have in-
creased. For example, in 2003 the Save a Sato Foundation,
which aims to relocate homeless dogs in Puerto Rico to
the US, transported roughly 14,000 dogs to the US (35).
Relocating animals to shelter environments in non-endemic
US regions and Canada could create R. sanguineus infesta-
tions within kennels, significantly impacting the prevalence
rates of foreign tick-borne pathogen strains within the local
dog population and exposing people to foreign, zoonotic
pathogens.
Co-infections complicate interpretation of the clinical
manifestations typically associated with single tick-
borne diseases in both canine and human medicine. Co-
infections can occur from simultaneous or sequential
exposure to several tick species, or when multiple patho-
gens are transmitted by a single tick (2, 3, 36). In our
study, co-exposures were defined as dogs seropositive to
two or more vector-borne pathogens. Overall, the co-
exposure seroprevalence rates were low. Combinations
with the highest seroprevalence rates were among patho-
gens known to share a common tick vector such as
EewEch in A. americanum and AphBb in I. scapularis.
Regional co-exposure seroprevalences were highest in
areaswhere the respective shared tick species are endemic,
including EewEch in the South and Mid-Atlantic, and
AphBb in the Northeast. Interestingly, the Mid-Atlantic
had the highest co-exposure seroprevalence rates for
several unexpected pathogen combinations including
EewBb, EchBb, and EchAph (Table 3). These co-
exposure combinations and seroprevalence rates highlight
the Mid-Atlantic as a potential region where I. scapularis
and A. americanum ticks and their respective pathogens
coalesce. As tick species migrate and habitats overlap,
co-exposures will likely be more common with the
potential for more disease severity. When monitoring
tick-borne diseases in regions like the Mid-Atlantic, co-
infections should be considered.
In conclusion, this study provides further support for
the use of dogs in tick-borne pathogen human surveil-
lance risks for several zoonotic infections of human and
veterinary medical importance. Over a relatively brief
time period, we demonstrated significant shifts in CVBD
seroprevalence rates including overall increases in Aph
and Ech, increases in Aph in the Mid-Atlantic and the
South and increases in Bb in the South. Furthermore,
by recognized species-specific seroprevalence, expected
and unique co-exposures were identified and highlight
the potential for tick-borne pathogen co-infections.
Combining dog and human tick-borne disease surveil-
lance data could enhance both public health and animal
health.
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